STOCK TITAN

[Form 4] Ingevity Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ingevity Corporation (NGVT) Form 4 filing: Director Francis David Segal reported the acquisition of 507 common shares on 07/01/2025 at an implied price of $44.40 per share. The shares were received through the vesting of deferred stock units (DSUs) elected in lieu of quarterly director fees under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following the transaction, Segal’s direct beneficial ownership increased to 5,241 shares. No derivative securities were involved, and the transaction was coded “A” (acquisition) rather than an open-market purchase or sale. Because DSUs settle only after board service ends, the filing signals continued equity alignment but does not represent immediate cash investment.

Ingevity Corporation (NGVT) Deposito del Modulo 4: Il direttore Francis David Segal ha segnalato l'acquisizione di 507 azioni ordinarie il 01/07/2025 a un prezzo implicito di 44,40 $ per azione. Le azioni sono state ricevute tramite la maturazione di unità azionarie differite (DSU) scelte in sostituzione delle commissioni trimestrali per i direttori nell'ambito del Piano di Compensazione Differita per Direttori Non Dipendenti e del Piano Omnibus Incentivi 2025 della società. A seguito della transazione, la proprietà diretta di Segal è aumentata a 5.241 azioni. Non sono stati coinvolti titoli derivati e la transazione è stata classificata come “A” (acquisizione) anziché come acquisto o vendita sul mercato aperto. Poiché le DSU si liquidano solo al termine del servizio nel consiglio, il deposito segnala un allineamento azionario continuo ma non rappresenta un investimento in contanti immediato.

Ingevity Corporation (NGVT) Presentación del Formulario 4: El director Francis David Segal reportó la adquisición de 507 acciones comunes el 01/07/2025 a un precio implícito de $44.40 por acción. Las acciones se recibieron mediante la consolidación de unidades de acciones diferidas (DSU) elegidas en lugar de las tarifas trimestrales para directores bajo el Plan de Compensación Diferida para Directores No Empleados y el Plan Omnibus de Incentivos 2025 de la empresa. Tras la transacción, la propiedad directa de Segal aumentó a 5,241 acciones. No se involucraron valores derivados, y la transacción se codificó como “A” (adquisición) en lugar de una compra o venta en el mercado abierto. Dado que las DSU se liquidan solo después de finalizar el servicio en la junta, la presentación indica una alineación continua con el capital, pero no representa una inversión en efectivo inmediata.

잉거비티 코퍼레이션(NGVT) Form 4 제출: 이사 프랜시스 데이비드 시걸은 2025년 7월 1일에 507주 보통주를 주당 $44.40의 암시적 가격으로 취득했다고 보고했습니다. 이 주식들은 회사의 비직원 이사 연기 보상 계획 및 2025년 종합 인센티브 계획에 따른 분기별 이사 수수료 대신 선택된 연기 주식 단위(DSU)의 베스팅을 통해 수령되었습니다. 거래 후 시걸의 직접 소유 주식은 5,241주로 증가했습니다. 파생 증권은 포함되지 않았으며, 거래는 공개 시장 매매가 아닌 “A”(취득)로 분류되었습니다. DSU는 이사회 서비스 종료 후에만 정산되므로, 이번 제출은 지속적인 주식 정렬을 의미하지만 즉각적인 현금 투자로는 간주되지 않습니다.

Dépôt du Formulaire 4 d'Ingevity Corporation (NGVT) : Le directeur Francis David Segal a déclaré l'acquisition de 507 actions ordinaires le 01/07/2025 à un prix implicite de 44,40 $ par action. Les actions ont été reçues par l'acquisition progressive d'unités d'actions différées (DSU) choisies en lieu et place des honoraires trimestriels des administrateurs dans le cadre du Plan de Compensation Différée pour Administrateurs Non Salariés et du Plan Incitatif Omnibus 2025 de la société. Suite à cette opération, la participation directe de Segal est passée à 5 241 actions. Aucun titre dérivé n'a été impliqué, et la transaction a été codée « A » (acquisition) plutôt que comme un achat ou une vente sur le marché ouvert. Étant donné que les DSU ne sont réglées qu'après la fin du mandat au conseil, ce dépôt indique un alignement continu sur le capital, mais ne constitue pas un investissement en liquidités immédiat.

Ingevity Corporation (NGVT) Form 4 Einreichung: Direktor Francis David Segal meldete den Erwerb von 507 Stammaktien am 01.07.2025 zu einem impliziten Preis von 44,40 $ pro Aktie. Die Aktien wurden durch die Vesting von aufgeschobenen Aktienanteilen (DSUs) erhalten, die anstelle der vierteljährlichen Direktorenvergütungen im Rahmen des Non-Employee Director Deferred Compensation Plan und des 2025 Omnibus Incentive Plan des Unternehmens gewählt wurden. Nach der Transaktion erhöhte sich Segals unmittelbarer wirtschaftlicher Eigentum auf 5.241 Aktien. Es waren keine Derivate beteiligt, und die Transaktion wurde als „A“ (Erwerb) codiert, nicht als Kauf oder Verkauf am offenen Markt. Da DSUs erst nach Beendigung der Vorstandsmitgliedschaft ausgezahlt werden, signalisiert die Meldung eine fortlaufende Beteiligungsausrichtung, stellt jedoch keine sofortige Barinvestition dar.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine DSU vesting adds 507 shares; modestly positive for alignment but immaterial to valuation.

The filing documents standard compensation rather than discretionary buying. While insider acquisitions are generally regarded as a vote of confidence, the 507-share increment (≈$22.5 k) is de minimis relative to NGVT’s float and lacks read-through for earnings or strategy. Because DSUs vest automatically and settle upon board departure, the director did not deploy fresh capital, so signaling value is muted. Nonetheless, cumulative ownership of 5,241 shares helps align director incentives with shareholder interests. Overall impact: neutral for valuation, slightly positive for governance.

Ingevity Corporation (NGVT) Deposito del Modulo 4: Il direttore Francis David Segal ha segnalato l'acquisizione di 507 azioni ordinarie il 01/07/2025 a un prezzo implicito di 44,40 $ per azione. Le azioni sono state ricevute tramite la maturazione di unità azionarie differite (DSU) scelte in sostituzione delle commissioni trimestrali per i direttori nell'ambito del Piano di Compensazione Differita per Direttori Non Dipendenti e del Piano Omnibus Incentivi 2025 della società. A seguito della transazione, la proprietà diretta di Segal è aumentata a 5.241 azioni. Non sono stati coinvolti titoli derivati e la transazione è stata classificata come “A” (acquisizione) anziché come acquisto o vendita sul mercato aperto. Poiché le DSU si liquidano solo al termine del servizio nel consiglio, il deposito segnala un allineamento azionario continuo ma non rappresenta un investimento in contanti immediato.

Ingevity Corporation (NGVT) Presentación del Formulario 4: El director Francis David Segal reportó la adquisición de 507 acciones comunes el 01/07/2025 a un precio implícito de $44.40 por acción. Las acciones se recibieron mediante la consolidación de unidades de acciones diferidas (DSU) elegidas en lugar de las tarifas trimestrales para directores bajo el Plan de Compensación Diferida para Directores No Empleados y el Plan Omnibus de Incentivos 2025 de la empresa. Tras la transacción, la propiedad directa de Segal aumentó a 5,241 acciones. No se involucraron valores derivados, y la transacción se codificó como “A” (adquisición) en lugar de una compra o venta en el mercado abierto. Dado que las DSU se liquidan solo después de finalizar el servicio en la junta, la presentación indica una alineación continua con el capital, pero no representa una inversión en efectivo inmediata.

잉거비티 코퍼레이션(NGVT) Form 4 제출: 이사 프랜시스 데이비드 시걸은 2025년 7월 1일에 507주 보통주를 주당 $44.40의 암시적 가격으로 취득했다고 보고했습니다. 이 주식들은 회사의 비직원 이사 연기 보상 계획 및 2025년 종합 인센티브 계획에 따른 분기별 이사 수수료 대신 선택된 연기 주식 단위(DSU)의 베스팅을 통해 수령되었습니다. 거래 후 시걸의 직접 소유 주식은 5,241주로 증가했습니다. 파생 증권은 포함되지 않았으며, 거래는 공개 시장 매매가 아닌 “A”(취득)로 분류되었습니다. DSU는 이사회 서비스 종료 후에만 정산되므로, 이번 제출은 지속적인 주식 정렬을 의미하지만 즉각적인 현금 투자로는 간주되지 않습니다.

Dépôt du Formulaire 4 d'Ingevity Corporation (NGVT) : Le directeur Francis David Segal a déclaré l'acquisition de 507 actions ordinaires le 01/07/2025 à un prix implicite de 44,40 $ par action. Les actions ont été reçues par l'acquisition progressive d'unités d'actions différées (DSU) choisies en lieu et place des honoraires trimestriels des administrateurs dans le cadre du Plan de Compensation Différée pour Administrateurs Non Salariés et du Plan Incitatif Omnibus 2025 de la société. Suite à cette opération, la participation directe de Segal est passée à 5 241 actions. Aucun titre dérivé n'a été impliqué, et la transaction a été codée « A » (acquisition) plutôt que comme un achat ou une vente sur le marché ouvert. Étant donné que les DSU ne sont réglées qu'après la fin du mandat au conseil, ce dépôt indique un alignement continu sur le capital, mais ne constitue pas un investissement en liquidités immédiat.

Ingevity Corporation (NGVT) Form 4 Einreichung: Direktor Francis David Segal meldete den Erwerb von 507 Stammaktien am 01.07.2025 zu einem impliziten Preis von 44,40 $ pro Aktie. Die Aktien wurden durch die Vesting von aufgeschobenen Aktienanteilen (DSUs) erhalten, die anstelle der vierteljährlichen Direktorenvergütungen im Rahmen des Non-Employee Director Deferred Compensation Plan und des 2025 Omnibus Incentive Plan des Unternehmens gewählt wurden. Nach der Transaktion erhöhte sich Segals unmittelbarer wirtschaftlicher Eigentum auf 5.241 Aktien. Es waren keine Derivate beteiligt, und die Transaktion wurde als „A“ (Erwerb) codiert, nicht als Kauf oder Verkauf am offenen Markt. Da DSUs erst nach Beendigung der Vorstandsmitgliedschaft ausgezahlt werden, signalisiert die Meldung eine fortlaufende Beteiligungsausrichtung, stellt jedoch keine sofortige Barinvestition dar.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Segal Francis David

(Last) (First) (Middle)
C/O INGEVITY CORPORATION
4920 O'HEAR AVE, SUITE 400

(Street)
NORTH CHARLESTON SC 29405

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Ingevity Corp [ NGVT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 507(1) A $44.4 5,241 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents vested deferred stock units ("DSUs") granted pursuant to the reporting person's election to receive DSUs in lieu of quarterly director fees. These DSUs will settle into an equal number of shares of the Company's Common Stock upon the reporting person's termination of board service pursuant to the Company's Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Remarks:
Francis David Segal By: Mavis G. Huger as Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NGVT shares did Director Francis D. Segal acquire?

He acquired 507 common shares through vested deferred stock units.

What is the director’s total NGVT ownership after the transaction?

Segal now directly owns 5,241 shares of Ingevity common stock.

Was the acquisition an open-market purchase?

No. The shares were received via vested DSUs under the company’s deferred compensation plan.

At what price were the shares valued in the Form 4?

The DSUs converted at an implied price of $44.40 per share.

Does this Form 4 suggest significant insider buying pressure on NGVT?

The transaction is small and compensation-driven, so it is not expected to materially affect insider buying trends or share price.
Ingevity Corp

NYSE:NGVT

NGVT Rankings

NGVT Latest News

NGVT Latest SEC Filings

NGVT Stock Data

1.57B
35.99M
0.93%
102.77%
3.17%
Specialty Chemicals
Chemicals & Allied Products
Link
United States
NORTH CHARLESTON